EC approves Vifor's Veltassa for hyperkalemia

Vifor Pharma Ltd. (SIX:VIFN) said the European Commission approved Veltassa patiromer to treat hyperkalemia, including patients who develop the condition while undergoing renin-angiotensin-aldosterone system (RAAS) inhibitor therapy. Vifor said the application was also approved in Norway, Liechtenstein and Iceland.

The company expects to launch Veltassa in those territories early next year. The drug is under regulatory review in Switzerland and Australia...